Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Oppenheimer Initiates Coverage On Windtree Therapeutics with Outperform Rating, Announces Price Target of $8

Oppenheimer analyst Leland Gershell initiates coverage on Windtree Therapeutics (NASDAQ:WINT) with a Outperform rating and announces Price Target of $8.

byBenzinga Newsdesk

June 4, 2021

1 minute read

Oppenheimer analyst Leland Gershell initiates coverage on Windtree Therapeutics (NASDAQ:WINT) with a Outperform rating and announces Price Target of $8.

Piper Sandler Maintains Overweight on Exelixis, Maintains $32 Price Target

By Benzinga Newsdesk

Today, 2:57 AM

Piper Sandler analyst Alexander Goldfarb maintains Exelixis (NASDAQ:EXEL) with a Overweight and maintains $32 price target.

EXEL

Why C4 Therapeutics Stock Is Plunging Today

By Adam Eckert

Today, 2:57 AM

C4 Therapeutics Inc (NASDAQ: CCCC) shares are trading significantly lower Friday afternoon after the company presented data from Cohort A of its ongoing Phase 1/2 clinical trial of CFT7455.

CCCC